These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30170009)

  • 1. In Situ Gel Formulation for Enhanced Ocular Delivery of Nepafenac.
    Shelley H; Rodriguez-Galarza RM; Duran SH; Abarca EM; Babu RJ
    J Pharm Sci; 2018 Dec; 107(12):3089-3097. PubMed ID: 30170009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation.
    Shelley H; Grant M; Smith FT; Abarca EM; Jayachandra Babu R
    AAPS PharmSciTech; 2018 Aug; 19(6):2554-2563. PubMed ID: 29948988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclodextrin-enabled nepafenac eye drops with improved absorption open a new therapeutic window.
    Vincze A; Facskó R; Budai-Szűcs M; Katona G; Gyarmati B; Csorba A; Zelkó R; Nagy ZZ; Szente L; Balogh GT
    Carbohydr Polym; 2023 Jun; 310():120717. PubMed ID: 36925244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers.
    Ke TL; Graff G; Spellman JM; Yanni JM
    Inflammation; 2000 Aug; 24(4):371-84. PubMed ID: 10850858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nepafenac loaded silica nanoparticles dispersed in-situ gel systems: Development and characterization.
    Paulsamy M; Ponnusamy C; Palanisami M; Nackeeran G; Paramasivam S; Sugumaran A; Kandasamy R; Natesan S; Palanichamy R
    Int J Biol Macromol; 2018 Apr; 110():336-345. PubMed ID: 29408555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
    Lindstrom R; Kim T
    Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.
    Senjoti FG; Timmins P; Conway BR; Smith AM
    Eur J Pharm Biopharm; 2020 Sep; 154():1-7. PubMed ID: 32599271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation.
    Lorenzo-Veiga B; Diaz-Rodriguez P; Alvarez-Lorenzo C; Loftsson T; Sigurdsson HH
    Nanomaterials (Basel); 2020 Apr; 10(4):. PubMed ID: 32283583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery.
    Noreen S; Ghumman SA; Batool F; Ijaz B; Basharat M; Noureen S; Kausar T; Iqbal S
    Int J Biol Macromol; 2020 Jun; 152():1056-1067. PubMed ID: 31751751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
    Bucci FA; Waterbury LD
    Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
    Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
    Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
    Trattler W; McDonald M
    Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
    Jones BM; Neville MW
    Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
    Colin J; Paquette B
    Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of levofloxacin loaded
    Jain P; Jaiswal CP; Mirza MA; Anwer MK; Iqbal Z
    Drug Dev Ind Pharm; 2020 Jan; 46(1):50-56. PubMed ID: 31818154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
    Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
    AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
    Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin.
    Wu C; Qi H; Chen W; Huang C; Su C; Li W; Hou S
    Yakugaku Zasshi; 2007 Jan; 127(1):183-91. PubMed ID: 17202799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.